N@N

Judah Frommer Maintained (ABOS) at Buy with Decreased Target to $16 on, Nov 15th, 2022

^{Published on 2024-10-28 00:09:57 - WOPRAI, Judah Frommer}
 

Judah Frommer of Credit Suisse, Maintained "Acumen Pharmaceuticals, Inc." (ABOS) at Buy with Decreased Target from $17 to $16 on, Nov 15th, 2022.

Judah has made no other calls on ABOS in the last 4 months.

There is 1 other peer that has a rating on ABOS. Out of the 1 peers that are also analyzing ABOS, 0 agree with Judah's Rating of Hold.

This is the rating of the analyst that currently disagrees with Judah

---

• Thomas Shrader of "BTIG" Maintained at Strong Buy with Increased Target to $22 on, Wednesday, October 5th, 2022

Contributing Sources

---